Previous 10 | Next 10 |
FDA grants two Orphan Drug Designations to KZR-616 for the treatment of Dermatomyositis (DM) and Polymyositis (PM) KZR-616 clinical and pre-clinical data continues to support its potential to positively affect multiple drivers of immune-mediated diseases KZ...
Clinical and pre-clinical data continues to support potential of KZR-616 to positively effect multiple drivers of immune-mediated diseases Kezar Life Sciences, Inc. (Nasdaq: KZR ), a clinical-stage biotechnology company discovering and developing breakthrough treatme...
Kala Pharmaceuticals on the go with upcoming PDUFA. Kezar announces Phase 2 KZR-616 trial update for polymyositis and dermatomyositis. Mirati Therapeutics announces positive clinical data for adagrasib. For further details see: Kala PDUFA, And Other News: The Good, Bad A...
Kezar Life Sciences (KZR) is up 6% in premarket on Orphan Drug status by the FDA for KZR-616 for the treatment of polymyositis ((PM)) and dermatomyositis ((DM)).PM is a type of muscle disease that leads to inflammation of muscles and their related tissues, like the blood vessels tha...
Kezar Life Sciences, Inc. (Nasdaq: KZR ), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that the U.S. Food and Drug Administration has granted Orphan Drug Designations (ODD) ...
– ACR and ASN presentations provide updated interim results from the Phase 1b MISSION study and highlight the broad immunomodulatory potential of KZR-616 to treat severe autoimmune diseases – Cytokines 2020 and SITC presentations to showcase Sec61 inhibition as a...
Kezar Life Sciences (NASDAQ: KZR ) is up 9% after hours in reaction to data from the Phase 1b portion of the Phase 1/2 MISSION study evaluating lead candidate KZR-616 in patients with systemic lupus erythematosus (SLE) and lupus nephritis (LN). The results were presented vi...
Kezar Life Sciences, Inc. (Nasdaq: KZR ), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today highlighted data from the Phase 1b portion of the MISSION study demonstrating safety, tolerability and earl...
Are These WeBull & Robinhood Penny Stocks On Your List This Week? Whether you’re looking for penny stocks to buy on Robinhood, WeBull, or other brokers, it’s good to have a strategy in place, first. One of the quickest ways to cut through the noise is to find companies with...
The following healthcare companies have filed for mixed shelf offerings: More news on: Citius Pharmaceuticals, Inc., Flexion Therapeutics, Inc., SCYNEXIS, Inc., Healthcare stocks news, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Kezar Life Sciences Inc. Company Name:
KZR Stock Symbol:
NASDAQ Market:
Kezar Life Sciences Inc. Website:
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer, today announced that Chris Kirk, Co-founder and Chief Executive Officer, will participate in a fireside chat at...
PALIZADE Phase 2b clinical trial of zetomipzomib in patients with active lupus nephritis actively enrolling; reiterating guidance of topline data in mid-2026 PORTOLA Phase 2a clinical trial of zetomipzomib in patients with autoimmune hepatitis actively enrolling; reiterating guidance of t...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...